title: Chemoprevention of breast cancer.
abstract: The development of pharmacologic agents for the prevention of breast cancer is a significant milestone in medical and laboratory research. Despite these advances, the endorsement of preventive options has become challenging and complex, as physicians are expected to counsel and tailor their recommendations using a personalized approach taking into account medical comorbidities, degree of risk and patient preferences. This article provides a comprehensive overview of the major breast cancer prevention trials, review of the pharmacologic options available for breast cancer prevention, and strategies for integrating chemoprevention of breast cancer in high-risk women into clinical practice.
authors.affiliation: Division of Women's Health Internal Medicine, Mayo Clinic in Arizona, 13737 North 92nd Street, Scottsdale, AZ 85260, USA. files.julia@mayo.edu
authors.forename: Julia A
authors.initials: JA
authors.lastname: Files
authors.forename: Daniela L
authors.initials: DL
authors.lastname: Stan
authors.forename: Summer V
authors.initials: SV
authors.lastname: Allen
authors.forename: Sandhya
authors.initials: S
authors.lastname: Pruthi
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000517:prevention & control*; D018890:Chemoprevention / Q000379:methods*; D002986:Clinical Trials as Topic; D005260:Female; D006266:Health Education / Q000379:methods; D006801:Humans; D057240:Patient Preference; D010817:Physician-Patient Relations; D057285:Precision Medicine / Q000379:methods*; D011322:Primary Prevention / Q000379:methods; D011788:Quality of Life; D018570:Risk Assessment; D016387:Women's Health
chemical_list: D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal